遠大醫(yi)藥(yao)(yao)集(ji)團有限(xian)公司(512.HK)是一家科技(ji)創新(xin)型國際(ji)化醫(yi)藥(yao)(yao)企業(ye)。集(ji)團的核(he)心產(chan)品(pin)涵(han)蓋抗(kang)腫瘤、心血管急救制(zhi)劑及心腦(nao)血管介(jie)入醫(yi)療(liao)器械(xie)、抗(kang)病(bing)毒抗(kang)感染、呼吸及五官科及生物健康產(chan)品(pin)和精(jing)品(pin)原料藥(yao)(yao)為(wei)代表的幾大業(ye)務領域(yu),形成了(le)以“創新(xin)壁壘藥(yao)(yao)械(xie)”、“品(pin)牌藥(yao)(yao)”、“原料制(zhi)劑一體化”和“健康產(chan)品(pin)”為(wei)主的四大業(ye)務結構,前(qian)瞻性(xing)布(bu)局全球創新(xin)和科技(ji)領先的三條賽道(dao),包括精(jing)準介(jie)入診療(liao),放射性(xing)核(he)素偶聯藥(yao)(yao)物(Radionuclide–drug conjugate,“RDC”)以及免疫治療(liao)。
集團充分發揮“精準和穏健的(de)(de)海內(nei)外業務拓展(zhan)能(neng)力,國(guo)際領(ling)(ling)先(xian)技(ji)術(shu)的(de)(de)引進消化(hua)落地(di)能(neng)力和優秀的(de)(de)市場推廣銷售能(neng)力”,瞄準科(ke)技(ji)創新前沿領(ling)(ling)域,以國(guo)際化(hua)和科(ke)技(ji)創新的(de)(de)視野不(bu)斷拓展(zhan)和落地(di)新的(de)(de)業績增長點,深(shen)度拓展(zhan)“心腦血管精準介入診療”、“抗腫瘤”以及“抗病毒抗感染(ran)”三個(ge)治療領(ling)(ling)域。
集團本著(zhu)積極開放(fang)的心態進(jin)行全球化研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)。全球研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心已初具雛形,全球化研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)布局已取得階段(duan)性成(cheng)(cheng)果(guo)。集團在全球范圍內布局了(le)四(si)個(ge)技(ji)術研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)平(ping)(ping)臺(tai)(tai)和(he)五個(ge)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心,前者由RDC技(ji)術平(ping)(ping)臺(tai)(tai)、DNA研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)技(ji)術平(ping)(ping)臺(tai)(tai)、mRNA研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)技(ji)術平(ping)(ping)臺(tai)(tai)及糖(tang)組學研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)技(ji)術平(ping)(ping)臺(tai)(tai)組成(cheng)(cheng),后者包括武(wu)漢光谷國際研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心(籌(chou)建(jian)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong))與四(si)個(ge)海外研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心(美國圣地亞(ya)哥研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心——免(mian)疫治療(DNA技(ji)術)抗腫(zhong)瘤(liu)、美國波士頓(dun)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心——精準介入抗腫(zhong)瘤(liu)、比利時研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心——mRNA、澳洲研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)(fa)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)心——抗病毒抗感染)。
未(wei)來,集團將繼續以滿足患者(zhe)需求為(wei)(wei)(wei)中心,以順(shun)應市場發展為(wei)(wei)(wei)方向,以堅持科技創(chuang)新為(wei)(wei)(wei)原(yuan)動力,秉(bing)承“綜合優勢、創(chuang)新壁壘和(he)全球(qiu)拓(tuo)展”的(de)發展理念,采用(yong)“自主研發和(he)全球(qiu)拓(tuo)展雙輪(lun)驅動,全球(qiu)化運營(ying)布局和(he)雙循環經營(ying)發展”策(ce)略,形成國(guo)內(nei)國(guo)際雙循環聯動發展并相互促進的(de)新格局,致(zhi)力于(yu)成為(wei)(wei)(wei)一家(jia)受醫生和(he)患者(zhe)尊重并還(huan)原(yuan)于(yu)社會(hui)的(de)科技創(chuang)新型(xing)國(guo)際化醫藥(yao)企(qi)業。